Target intelligence / Profile preview

Nipsnap homolog 2 (NIPSNAP2)

Target
NIPSNAP2
Molecular classification
NipSnap protein family, Mitochondrial protein, Other (not classified as receptor, ion channel, enzyme, transporter, or transcription factor)
01

Overview

Nipsnap homolog 2 (NIPSNAP2, also known as GBAS or glioblastoma amplified sequence) is a member of the NipSnap protein family and is encoded by the GBAS gene on chromosome 7p12. NIPSNAP2 is localized primarily to mitochondria, where it participates in maintaining mitochondrial health, most notably through facilitating the selective autophagic clearance of damaged mitochondria (mitophagy) by recruiting core autophagy machinery and "eat me" signals. It interacts with proteins involved in vesicular transport, and its expression is highest in skeletal muscle and heart tissue. The region containing the GBAS gene is amplified in a significant proportion of glioblastoma cases, suggesting a potential role in cancer, although it is not currently an established therapeutic target. NIPSNAP2 is implicated in cellular processes such as metabolism and oxidative phosphorylation, and may play a role in neurodegenerative diseases including Parkinson’s disease by modulating mitochondrial quality control systems[1][2][3][5][7].

Other names
GBASGlioblastoma amplified sequenceNipSnap2Protein NipSnap homolog 2
02

Mechanism of action

Clarithromycin: transient functional inhibition of mitochondria via direct binding to NIPSNAP2, decreasing mitochondrial activity and modulating immunomodulatory effects. No established therapeutic mechanisms of action for direct targeting.

03

Biological functions

Mitochondrial homeostasisMitophagy (clearance of damaged mitochondria)Vesicular transportOxidative phosphorylation supportRegulation of mitochondrial metabolism
04

Disease associations

Cancer (chromosomal region containing GBAS is amplified in ~40% of glioblastomas)Parkinson’s disease (mitophagy, mitochondrial health)Mast syndrome (gene-disease association)Phosphoserine phosphatase deficiency (gene-disease association)Neurodegenerative disease (general link via mitophagy/Parkinson’s)Other (role as a general sensor of mitochondrial health)
05

Safety considerations

None specifically documented for therapeutic targeting, as NIPSNAP2 is not an approved drug targetPotential challenges: essential role in mitochondrial homeostasis, possible adverse effects if inhibited/disrupted
06

Interacting drugs

Clarithromycin (CAM)
07

Biomarkers

Amplification of GBAS chromosomal region (glioblastoma)NIPSNAP2 expression (skeletal muscle/heart)Not established as a clinically used biomarker for patient selection or efficacy monitoring

Beyond the preview

Go deeper on Nipsnap homolog 2 (NIPSNAP2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nipsnap homolog 2 (NIPSNAP2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call